Skip to main content

Advertisement

SpringerLink
Log in

Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Background Altered DNA repair capacity due to polymorphisms in DNA repair genes may modify response to Bacillus Calmette–Guerin (BCG) immunotherapy for high risk superficial bladder cancer (SBC).We evaluated the prospective outcome of exicision repair cross complementing group 2 (ERCC2) and apurinic/apyriminidic endonuclease (APEX1) gene in tumor recurrence after BCG immunotherapy in SBC patients. Materials and methods The study included 135 SBC patients, of which BCG immunotherapy was received by 74 patients. Genotyping was performed for ERCC2 Asp312Asn (G > A), Lys751Gln (A > C), and APEX1 Asp148Glu (T > G) polymorphisms by restriction fragment length polymorphism PCR and amplification refractory mutation system (ARMS) methods. Results Multiple Cox regression analysis demonstrated association of variant genotype of ERCC2312AA polymorphism with high risk of recurrence in BCG treated patients (HR = 3.07, P = 0.016, P c  = 0.048). Patients with the ERCC2312AA polymorphic genotypes showed shorter recurrence free survival (log-rank, P = 0.005; AA/GA + AA = 14/44) who received BCG treatment. Overall, risk of recurrence in bladder cancer was observed with smokers and size of tumors (1–3 cm) (HR = 1.86, P = 0.023 and HR = 3.19, P = 0.031, respectively). Smokers were identified to be at elevated risk in BCG treated patients (HR = 2.84, P = 0.005). No association was observed with the (ERCC2 Lys751Gln and APEX1 Asp148Glu) polymorphisms and risk of recurrence. Conclusion Our data suggested variant (AA) of ERCC2 312 AA genotype to be associated with high risk of tumor recurrence and reduced recurrence free survival in superficial bladder cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Meyer JP, Persad R, Gillatt DA. Use of Bacille Calmette–Guérin in superficial bladder cancer. Postgrad Med J. 2002;78:449–54. doi:10.1136/pmj.78.922.449.

    Article  PubMed  Google Scholar 

  2. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311–22. doi:10.1046/j.1523-5394.2002.106011.x.

    Article  PubMed  Google Scholar 

  3. Merz VW, et al. Analysis of early failures after intravesical instillation therapy with Bacille Calmette–Guerin for carcinoma in situ of the bladder. Br J Urol. 1995;75:180–4. doi:10.1111/j.1464-410X.1995.tb07307.x.

    Article  CAS  PubMed  Google Scholar 

  4. Zhou W, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:359–65.

    CAS  PubMed  Google Scholar 

  5. Gu J, et al. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res. 2005;11:1408–15. doi:10.1158/1078-0432.CCR-04-1101.

    Article  CAS  PubMed  Google Scholar 

  6. Schaeffer L, et al. The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor. EMBO J. 1994;13:2388–92.

    CAS  PubMed  Google Scholar 

  7. Coin F, Bergmann E, Tremeau-Bravard A, Egly JM. Mutations in XPB and ERCC2 helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH. EMBO J. 1999;18:1357–66. doi:10.1093/emboj/18.5.1357.

    Article  CAS  PubMed  Google Scholar 

  8. Bennett RA, Wilson DM, Wong D, Demple B. Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway. Proc Natl Acad Sci. 1997;94:7166–9. doi:10.1073/pnas.94.14.7166.

    Article  CAS  PubMed  Google Scholar 

  9. Lu AL, Li X, Gu Y, Wright PM, Chang DY. Repair of oxidative DNA damage: mechanisms and functions. Cell Biochem Biophys. 2001;35:141–70. doi:10.1385/CBB:35:2:141.

    Article  CAS  PubMed  Google Scholar 

  10. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.

    CAS  PubMed  Google Scholar 

  11. Sobin LH, Wittekind Ch. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002. p. 199–202.

    Google Scholar 

  12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1998;16:1215. doi:10.1093/nar/16.3.1215.

    Article  Google Scholar 

  13. Rybicki BA, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;1:23–9. doi:10.1158/1055-9965.EPI-03-0053.

    Article  Google Scholar 

  14. Sanyal S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34. doi:10.1093/carcin/bgh058.

    Article  CAS  PubMed  Google Scholar 

  15. Ito H, et al. Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis. 2004;25:1395–401. doi:10.1093/carcin/bgh153.

    Article  CAS  PubMed  Google Scholar 

  16. Leibovici D, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005;23:5746–56. doi:10.1200/JCO.2005.01.598.

    Article  CAS  PubMed  Google Scholar 

  17. Gangwar R, Manchanda PK, Mittal RD. Implications of XRCC1, XPD and APE1 gene polymorphism in North Indian population: a comparative approach in different ethnic groups worldwide. Genetica. 2008 [Epub ahead of print].

  18. Bohle A, Brandau S. Immune mechanisms in Bacillus Calmette–Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964–9. doi:10.1097/01.ju.0000073852.24341.4a.

    Article  PubMed  Google Scholar 

  19. Mitra S, Boldogh I, Izumi T, Hazra TK. Complexities of the DNA base excision repair pathway for repair of oxidative DNA damage. Environ Mol Mutagen. 2001;38:180–90. doi:10.1002/em.1070.

    Article  CAS  PubMed  Google Scholar 

  20. Sanyal S, De Verdier PJ, Steineck G, Larsson P, Onelöv E, Hemminki K, et al. Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms. Acta Oncol. 2007;46:31–41. doi:10.1080/02841860600812693.

    Article  CAS  PubMed  Google Scholar 

  21. Huang M, Dinney CP, Lin X, Lin J, Grossman HB, Wu X. High-order interactions among genetic variants in DNA BER pathway and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2007;16:84–91. doi:10.1158/1055-9965.EPI-06-0712.

    Article  CAS  PubMed  Google Scholar 

  22. Schabath MB, Delclos GL, Grossman HB, Wang Y, Lerner SP, Chamberlain RM, et al. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:878–84. doi:10.1158/1055-9965.EPI-04-0235.

    Article  CAS  PubMed  Google Scholar 

  23. Stern MC, Johnson LR, Bell DA, Taylor JA. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1004–11.

    CAS  PubMed  Google Scholar 

  24. Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC, Casella DP, et al. Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis. 2006;27:1030–7. doi:10.1093/carcin/bgi284.

    Article  CAS  PubMed  Google Scholar 

  25. Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, Eguchi S, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer. 2006;9:561–70. doi:10.1038/sj.bjc.6603290.

    Article  Google Scholar 

  26. Wang F, Chang D, Hu F, Sui H, Han B, Li D, et al. DNA repair gene XPD polymorphisms and cancer risk: a meta-analysis based on 56 case-control studies. Cancer Epidemiol Biomarkers Prev. 2008;17:507–17.

    Article  CAS  PubMed  Google Scholar 

  27. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 2001;61:1354–7.

    CAS  PubMed  Google Scholar 

  28. Hou SM, Falt S, Angelini S, Yang K, Nyberg F, Lambert B, et al. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis. 2002;23:599–603. doi:10.1093/carcin/23.4.599.

    Article  CAS  PubMed  Google Scholar 

  29. Capella G, Pera G, Sala N, Agudo A, Rico F, Giudicce GD, et al. DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. Int J Epidemiol. 2008;37:1316–25. doi:10.1093/ije/dyn145.

    Article  PubMed  Google Scholar 

  30. de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol. 2006;17:668–75. doi:10.1093/annonc/mdj135.

    Article  Google Scholar 

  31. Hansen RD, Sørensen M, Tjønneland A, Overvad K, Wallin H, Raaschou-Nielsen O, et al. XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. Mutat Res. 2007;619:68–80. doi:10.1016/j.mrfmmm.2007.02.002.

    CAS  PubMed  Google Scholar 

  32. Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, et al. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol. 2007;107(Suppl 1):S223–9. doi:10.1016/j.ygyno.2007.07.024.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The study was supported by the grant of Department of Science and Technology, New Delhi Government of India, RG is thankful to Council of Scientific and Industrial Research, New Delhi for JRF and DA is thankful to Department of Biotechnology, Pune for SRF.

Funding agency

Department of Science and Technology, New Delhi Government of India.

Author information

Authors and Affiliations

  1. Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow, Uttar Pradesh, 226014, India

    Ruchika Gangawar, Dinesh Ahirwar, Anil Mandhani & Rama Devi Mittal

Authors
  1. Ruchika Gangawar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dinesh Ahirwar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anil Mandhani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rama Devi Mittal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rama Devi Mittal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gangawar, R., Ahirwar, D., Mandhani, A. et al. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India. Med Oncol 27, 159–166 (2010). https://doi.org/10.1007/s12032-009-9187-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9187-y

Keywords

Search

Navigation